IL33 and endometrial cancer: Later, the same authors [91] conducted another study about IL-31 and IL-33 in endometrial-cancer patients: they found higher expression of IL-31, IL-31R, IL-33, and ST2 in malignant tissue than in the healthy control group, and they observed that a stronger expression of IL-31 and IL-33, as well as their receptors, were associated with a worse stage and a worse prognosis.